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Abstract: Atopic dermatitis (AD) is the foremost non-fatal skin-related disease that affects all age groups.
Despite the growing prevalence of AD in low- and middle-income countries, its physiological conse-
quences remain overlooked in countries like Bangladesh. Therefore, we aim to assess and characterize the
influence of AD on the health-related quality of life (HRQoL) in Bangladeshi patients. A cross-sectional
study comprising 184 eligible adults (83 men and 101 women; mean age, 33.46 ± 15.44 years) was con-
ducted at the dermatology outpatient department of Shaheed Suhrawardy Medical College Hospital
(a tertiary hospital in Dhaka, Bangladesh). AD was determined using the UK Working Party criteria.
A structured questionnaire, Eczema Area and Severity Index (EASI), and Dermatology Life Quality Index
(DLQI) were administered to obtain information on patient characteristics, AD severity, and HRQoL.
The mean DLQI score for the entire sample was 11.29 ± 5.27 (range, 1–26), and 51.60% reported the disease
greatly affected their lives. Bivariate analysis revealed significant differences in self-rated health measures
of DLQI scores in terms of self-reported AD severity, overall health, and the EASI. In multivariable regres-
sion models adjusted for patient characteristics, the self-perceived severe AD group reported significantly
higher DLQI scores (coefficient = 2.72; 95% confidence interval (CI) = 0.38–5.05; p = 0.022) than the mild
group. Concurrently, we observed a substantial increase in the DLQI scores among patients with mod-
erate and severe EASI scores (coefficient = 1.96, 95% CI = 0.08–3.92, p < 0.05 and coefficient = 4.35,
95% CI = 1.98–6.72, p < 0.001, respectively) than in those with mild EASI scores, suggesting that
HRQoL was markedly influenced by greater AD severity. These findings highlight the need for a
more patient-centric approach to the management of AD in order to alleviate patient suffering and, thereby,
improve HRQoL.
Keywords: atopic dermatitis; disease severity; Dermatology Life Quality Index; Eczema Area and
Severity Index; health-related quality of life
1. Introduction
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder character-
ized by frequent exacerbations of pruritic and eczematous lesions [1]. The pathogenesis
of AD is complex and involves genetic susceptibility, abnormal skin barrier function,
dysfunctional cell-mediated immunity, and environmental and lifestyle factors [1,2].
AD affects people of all ages, but it typically manifests in early infancy or childhood,
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persists into adulthood, and chronically affects patients throughout their lives [1,3].
However, new-onset AD can also develop in adults, and, hence, studies on adult-onset
AD have increased [3,4]. This heterogeneous skin disorder with wide-ranging clinical
manifestations, including inflammatory infiltration, intense pruritus, and skin pain,
can impose a profound burden on patients [4,5]. According to the Global Burden of
Disease project, AD contributes to the highest disease burden among all skin disorders,
as measured using disability-adjusted life years, and ranks 15th among all non-fatal
diseases [6]. Moreover, AD may lead to psychological stress due to stigmatization,
impaired physical and social functioning, and sleep disturbance, thereby considerably
undermining different aspects of a patient’s health-related quality of life (HRQoL) [7,8].
HRQoL is a multidimensional concept that reflects an individual’s subjective feeling
of health; it has become an essential indicator for patient health in dermatology as skin
diseases are usually long-lasting and have a marked impact on a patient’s life [8,9]. Many
studies have highlighted the relevance of HRQoL in adults with AD [5,7,8]. Compared
to the general population and those with other chronic diseases such as diabetes mellitus
and heart disease, adult patients with AD show a decrease in HRQoL [7]. Evidence
also suggests that adults with AD experience embarrassment, self-consciousness, and
interference with personal and social relationships, emotional state, work performance, and
daily activities [7]. Therefore, dermatologists are strongly encouraged to examine patients’
psychological aspects, of which HRQoL is a good indicator. In patients with AD, HRQoL is
affected by greater AD severity (especially when the affected body surface area is larger),
pruritus severity, skin pain, frequency of sleep disturbance, and skin dryness [7,8,10].
Consequently, the quantification of HRQoL related to AD severity is being increasingly
emphasized since this assessment provides additional information for patient management.
AD has been linked to a significant disease burden in Asian countries and has an impact
on the quality of life (QoL) of the patients and their families [11]. Moreover, in recent decades,
the prevalence of AD in Asia, including low- and middle-income countries (LMICs), has seen
an increase, probably because of increasing urbanization, westernized lifestyles, and improved
living standards [11,12]. Notably, owing to the higher rates of disease onset during adulthood,
the prevalence of AD in adults seems to be greater in some Asian populations than in other
populations [12]. However, age of onset, disease severity, and genetic susceptibility may
differ between and within countries as well as between rural and urban areas [13]. Therefore,
understanding the psychological influence of AD and characterizing it in each population is
imperative to alleviate patient suffering and optimize care. Moreover, as AD is incurable, patient
satisfaction and HRQoL improvement in accordance with symptom reduction have become
increasingly vital in clinical decision-making [8].
While the psychological burden of AD is well documented in high-income coun-
tries (HICs), including those in Asia, its effects have rarely been investigated in LMICs.
In Bangladesh, AD is one of the most common skin diseases, and its prevalence has been
increasing recently [14,15]. However, the psychological aspects of AD in Bangladeshi adults
have not yet been evaluated. Hence, the objective of this study is to evaluate HRQoL and
characterize factors that influence HRQoL among Bangladeshi adults with AD by using
the Bangla version of the Dermatology Life Quality Index (DLQI). The DLQI has been
well-validated and widely used to measure subjective impairment in several dermatologic
conditions, including AD [16]. Additionally, we examined the reliability of the Bangla
version of the DLQI.
2. Materials and Methods
2.1. Study Design and Participants
A non-interventional, cross-sectional study was performed to assess HRQoL and asso-
ciated factors in patients with AD. Participants for this study were recruited consecutively
between January and April 2021 from among the patients who visited the dermatology
outpatient department of the Shaheed Suhrawardy Medical College Hospital (a tertiary
hospital in Dhaka, Bangladesh). The inclusion criteria were as follows: (a) patients with AD,
(b) aged 16 years or older, (c) able to communicate in Bangla language, and (d) voluntarily
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agreeing to participate after providing written informed consent. Patients with any of the
following conditions were excluded: (a) pregnant or lactating women, (b) patients with
mental illness, and (c) patients having difficulty completing the surveys. We adopted the
UK Working Party (UKWP) criteria to identify patients with AD [17]. This included all
characteristics of the UKWP criteria, including skin itchiness during the last 12 months
and three or more of the following: history of (1) skin crease involvement, (2) asthma or
hay fever, (3) general dry skin during the past year, (4) visible flexural eczema, or (5) onset
before the age of 2 years. Patients who met the inclusion criteria were invited to participate
in the study. Patients with active dermatological diseases other than AD were excluded
from the final analysis. Throughout the study, patient identification and disease severity
examination were performed by one dermatologist, and this was followed by an interview
by a trained enumerator.
2.2. Measurement Tools
2.2.1. Measurement of AD Severity
Disease severity was assessed using the Eczema Area and Severity Index (EASI),
which is a broadly used and validated tool for measuring the severity of AD [18]. The
EASI was applied to structure the observations because it is simple, easy to understand,
and can be used by practitioners to normalize the baseline evaluation of the condition
and track changes over time. The EASI encompasses an assessment of disease extent
on a scale of 0–6 in four affected body parts (head/neck, trunk, and upper and lower
extremities) and an evaluation of erythema, infiltration/papulation, excoriation, and
lichenification, each scored on a scale of 0–3. The sum of these scores yields the EASI,
which ranges from 0 to 72. A higher EASI score indicates extensive and severe disease
conditions. In our study, we divided patients with AD into groups of equal percentiles
based on their EASI scores: mild (<9), moderate (9–15), and severe (>15), as no cutoff
values had been proposed for this measure.
2.2.2. Measurement for HRQoL
A 1-week-recall, Bangla edition of the DLQI questionnaire was administered as a
self-assessment of the patients’ HRQoL. The DLQI is a dermatology-specific question-
naire designed for adults (i.e., patients aged > 16 years) to evaluate any skin disorder
that affects different aspects of their lives over the previous week [16,19,20]. The DLQI
consists of 10 items evaluating disease impact on key aspects of patient lives and is
distributed across six domains related to symptoms and feelings (Questions 1 and 2),
daily activities (3 and 4), leisure (5 and 6), work and study (7), personal relationships
(8 and 9), and treatment (10), as well as an overall DLQI score. Each DLQI question has
four response categories (“not at all”, “a little”, “a lot”, and “very much”) that are scored
on a 0–3 Likert scale. The overall DLQI is the total score of all questions and ranges
from 0 to 30, with a higher score indicating increased QoL impairment. The overall
DLQI score can be classified into five groups according to the influence on the patients’
HRQoL: no effect (0–1), a small effect (2–5), a moderate effect (6–10), a very large effect
(11–20), and an extremely large effect (21–30).
2.2.3. Self-Assessed AD Severity, Overall Health, and Other Study Variables
To obtain the patients’ subjective appraisal of their condition, we chose a combination
of three questions dealing with previously validated “self-reported global AD severity”
(how would you describe your AD: mild, moderate, or severe) [21] and “self-assessment
of overall health” (how would you describe your overall health: poor, fair, good, or
excellent). The demographic data collected included age, sex (male/female), educational
level (≤primary, secondary, and ≥tertiary), marital status (single/married), and residence
(rural/urban). We also collected information on current smoking (yes/no), family history
of AD (yes/no), and allergic complications (yes/no). All the questionnaires (except for the
DLQI questionnaire) were first prepared in English and then translated into Bangla.
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2.3. Data Analysis
The sample size for this study was determined using G Power 3.1 software [22] based
on a significance level of 0.05, a power of 0.95, and a medium-size effect of 0.15. The analysis
revealed that 178 participants were required for the analysis. Patient characteristics were
expressed as frequencies, percentages, means, and standard deviations. First, the internal
consistency reliability of the DLQI items was examined using Cronbach’s α coefficients and
item-total correlations. Cronbach’s α, which is a highly relevant method to measure the
reliability of a scale containing multiple items, was defined for the overall instrument [16].
Cronbach’s α coefficient value of not less than 0.7 is generally considered sufficient to
demonstrate internal consistency [16,23]. For item-total correlation, a value of >0.3 is
considered to indicate that an item is connected to the overall scale [23]. Bivariate and
multivariable analyses were performed to identify the factors influencing HRQoL among
patients with AD. First, a bivariate analysis was conducted to explore the differences across
the patients’ general characteristics using domain-specific DLQI and overall DLQI scores.
Non-parametric approaches, the Mann–Whitney U-test and the Kruskal–Wallis test, were
used because the variables had a non-normal distribution according to the Shapiro–Wilk
test. Subsequently, posthoc F tests were performed to detect any potential differences
between the groups.
Second, multiple linear regression analyses were adopted to determine the association
between illustrative variables: domain-specific DLQI, overall DLQI, and patient characteris-
tics. Individual variables that showed statistical significance (p < 0.05) at the bivariate level
were included in the regression model. Domain-specific DLQI (symptoms and feelings,
daily activities, leisure, work and school, personal relationships, and treatment) and overall
DLQI scores were used separately as dependent variables in the model, and the potential
confounders adjusted for were marital status, family history of AD, self-reported global AD
severity, overall health ratings, and EASI scores. We included the variance inflation factor
(VIF) in each regression model to check for multicollinearity; however, none of the variables
exceeded a VIF > 2.0. The beta coefficient was also determined to evaluate the strength of
the association with a 95% confidence interval (CI). The significance level was set to p < 0.05.
Statistical analyses were performed using IBM SPSS Statistics for Windows/Macintosh,
Version 25.0 (IBM Corp., Armonk, NY, USA).
3. Results
3.1. Patient Characteristics
Of the 198 patients enrolled, 14 were excluded because they had active skin dis-
eases other than AD, thus leaving 184 to be included in the final analysis (Figure 1).
Table 1 presents the descriptive characteristics of the patients. The participants included
83 men (45.10%) and 101 women (54.90%) with a mean age (±standard deviation) of
33.46 ± 15.44 years (range, 16–70 years), and the highest proportion of patients was
in the age group below 30 years (54.30%). In total, 52.20% of patients had completed
tertiary education, and 57.60% were married. Moreover, 97 (52.70%) patients reported
having a family history of AD, and 98 (53.30%) had allergy complications. In terms
of self-reported global AD severity, 21 (11.40%) patients reported having mild AD,
51 (27.70%) as having moderate AD, and 112 (60.90%) as having severe AD. The over-
all health rating of the patients was poor in 37 (20.10%), fair in 35 (19.00%), good in
98 (53.30%), and excellent in 14 (7.60%). The distribution of disease severity was ex-
pressed on the basis of the cutoff value of the EASI score. The severity of AD was mild,
moderate, and severe in 33 (17.90%), 97 (52.70%), and 54 (29.40%) patients, respectively.
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Table 1. Demographic and clinical characteristics of the patients with AD (n = 184). 
Variable n (%) 
Sex Male 83 (45.10) Female 101 (54.90) 
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30–50 55 (29.90) 
>50 29 (15.80) 
Level of education 
≤Primary 64 (34.80) 
Secondary 24 (13.00) 
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Marital status Single 78 (42.40) Married 106 (57.60) 
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Smoking Yes 20 (10.90) No 164 (89.10) 
Family history of AD Yes 97 (52.70) No 87 (47.30) 
Allergic complications Yes 98 (53.30) No 86 (46.70) 
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Mild (<9) 33 (17.90)
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Severe (>16) 54 (29.40)
AD: atopic dermatitis; EASI: Eczema Area and Severity Index.
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3.2. Descriptive Summary of DLQI Scale Scores, Internal Consistency, and Overall HRQoL
The descriptive summary and internal consistency reliability of the DLQI items are
presented in Table 2. The internal reliability coefficient (measured using Cronbach’s α)
for the DLQI was 0.75. As shown in Table 2, Cronbach’s α ranged between 0.71 and 0.76
for all 10 items of the DLQI questionnaire, indicating good internal consistency and no
redundant items. The item-total correlation for all the 10 items exhibited good correlation
(ranging between 0.23 and 0.63), except for Item 9. The mean overall DLQI score for the
whole sample was 11.29 ± 5.27 (range, 1–26). Of the 10 DLQI scales, the highest score
was recorded for Question 1 (itchy and painful; 2.15 ± 1.08), followed by Question 2
(embarrassment; 1.89 ± 1.06). Figure S1 represents the distribution of patient responses
on the DLQI items. Based on the overall DLQI score classification, only 2.7% of patients
reported AD having “no effect on their life”, while 28.80% and 51.60% of patients reported
AD having “mild” and “very large effect on their life”, respectively (Table 3).
Table 2. Summary descriptive statistics and internal consistency reliability of the DLQI items.
DLQI Item Mean (SD) Reliability
Cronbach’s α coefficient Item-total correlation
Itchy, painful 2.15 (1.08) 0.737 0.437
Embarrassed 1.89 (1.06) 0.718 0.551
Interfered with shopping,
housework 0.98 (1.04) 0.722 0.530
Influenced clothes 1.07 (1.11) 0.744 0.395
Affected social activities 0.67 (0.85) 0.711 0.636
Affected sports 0.47 (0.78) 0.749 0.340
Prevented work 1.11 (0.75) 0.753 0.304
Problem with friends 0.74 (0.87) 0.734 0.461
Sexual difficulties 0.47 (0.73) 0.760 0.237
Treatment problematic 1.75 (0.97) 0.752 0.326
Total DLQI score 11.29 (5.27)
Values of DLQI items expressed as mean ± SD. DLQI: Dermatology Life Quality Index; SD: standard deviation.
Table 3. Distribution of patients with AD based on the DLQI score ranges and their significance on
the patients’ lives.
DLQI Score Range Meaning of Scores n %
0–1 No effect at all onpatient’s life 5 2.70
2–5 Small effect onpatient’s life 26 14.20
6–10 Moderate effect onpatient’s life 53 28.80
11–20 Very large effect onpatient’s life 95 51.60
21–30 Extremely large effecton patient’s life 5 2.70
AD: atopic dermatitis; DLQI: Dermatology Life Quality Index.
3.3. HRQoL According to Patient Demographic Characteristics
The association between domain-specific and overall DLQI and patient demographic
characteristics at the bivariate level is shown in Table 4. Significant differences in self-rated
health measures of domain-specific DLQI and overall DLQI scores were found in relation
to marital status and family history of AD. Scores of “daily activities”, “leisure”, “personal
relationship”, and overall DLQI were significantly higher in the married group than in the
single group. Patients who had a family history of AD reported higher scores in “symptoms
and feelings”, “daily activities”, “leisure”, “personal relationship”, and overall DLQI.
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Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Sex
Male 3.93 ± 1.79 1.84 ± 1.65 1.31 ± 1.63 1.17 ± 0.71 1.19 ± 1.24 1.66 ± 0.94 11.11 ± 5.50
Female 4.13 ± 1.81 2.22 ± 1.70 0.99 ± 1.10 1.06 ± 0.78 1.23 ± 1.22 1.82 ± 1.00 11.45 ± 5.09
p 0.367 0.098 0.460 0.277 0.745 0.310 0.667
Age
<30 3.96 ± 1.84 1.84 ± 1.69 0.98 ± 1.31 1.10 ± 0.77 0.96 ± 1.08 1.67 ± 0.98 10.51 ± 5.12
30–50 3.98 ± 1.66 2.25 ± 1.68 1.27 ± 1.45 1.16 ± 0.71 1.65 ± 1.41 1.93 ± 1.01 12.25 ± 5.60
>50 4.41 ± 1.93 2.38 ± 1.63 1.41 ± 1.37 1.03 ± 0.77 1.24 ± 1.12 1.69 ± 0.85 12.17 ± 4.83
p 0.371 0.121 0.096 0.718 0.051 0.256 0.088
Level of
education
≤Primary 4.28 ± 1.74 2.28 ± 1.65 1.27 ± 1.46 1.20 ± 0.76 1.31 ± 1.15 1.86 ± 1.00 12.20 ± 5.02
Secondary 3.46 ± 2.00 1.67 ± 1.65 1.17 ± 1.68 1.00 ± 0.59 1.13 ± 1.32 1.92 ± 0.92 10.33 ± 6.02
≥Tertiary 4.02 ± 1.77 1.99 ± 1.70 1.04 ± 1.23 1.07 ± 0.78 1.17 ± 1.26 1.64 ± 0.96 10.93 ± 5.20
p 0.196 0.233 0.611 0.450 0.456 0.217 0.206
Marital
status
Single 3.83 ± 1.81 1.72 ± 1.69 0.91 ± 1.34 1.09 ± 0.79 0.88 ± 1.03 1.59 ± 0.98 10.03 ± 5.08
Married 4.19 ± 1.78 2.29 ± 1.64 1.30 ± 1.38 1.12 ± 0.72 1.45 ± 1.31 1.87 ± 0.95 12.23 ± 5.23
p 0.198 0.010 0.013 0.969 0.002 0.065 0.005
Residence
Rural 4.03 ± 1.68 2.13 ± 1.68 1.33 ± 1.43 1.08 ± 0.65 1.33 ± 1.20 1.75 ± 0.98 11.63 ± 5.11
Urban 4.04 ± 1.83 2.03 ± 1.69 1.08 ± 1.35 1.12 ± 0.78 1.18 ± 1.23 1.75 ± 0.97 11.20 ± 5.32
p 0.821 0.750 0.202 0.850 0.418 0.992 0.654
Smoking
Yes 4.20 ± 1.67 2.00 ± 1.86 1.45 ± 1.66 1.25 ± 0.63 1.35 ± 1.34 1.90 ± 0.78 12.15 ± 5.86
No 4.02 ± 1.82 2.05 ± 1.67 1.10 ± 1.33 1.09 ± 0.76 1.20 ± 1.21 1.73 ± 0.99 11.19 ± 5.20




Yes 4.46 ± 1.58 2.35 ± 1.68 1.43 ± 1.36 1.16 ± 0.73 1.43 ± 1.31 1.79 ± 0.91 12.64 ± 4.82
No 3.56 ± 1.92 1.71 ± 1.63 0.80 ± 1.31 1.05 ± 0.77 0.97 ± 1.08 1.70 ± 1.04 9.79 ± 5.36
p 0.003 0.007 0.002 0.253 0.012 0.539 <0.001
Allergic com-
plications
Yes 4.02 ± 1.83 2.06 ± 1.53 1.28 ± 1.44 1.00 ± 0.70 1.18 ± 1.21 1.68 ± 0.98 11.22 ± 5.15
No 4.06 ± 1.77 2.03 ± 1.85 0.98 ± 1.28 1.23 ± 0.79 1.24 ± 1.25 1.83 ± 0.97 11.37 ± 5.43
p 0.923 0.571 0.103 0.052 0.745 0.303 0.850
Values of domain-specific and overall DLQI expressed as mean ± SD. DLQI: Dermatology Life Quality Index; SD: standard deviation;
AD: atopic dermatitis; EASI: Eczema Area and Severity Index; p-value calculated using the Mann–Whitney U-test or Kruskal–Wallis test;
values in bold are significant.
3.4. HRQoL According to Patient Self-Perceived AD Severity, Overall Health Rating, and the EASI
Bivariate association between the patients’ HRQoL and self-perceived AD severity,
overall health rating, and the EASI are shown in Table 5 and Figure 2. A significant
difference was observed in “symptoms and feelings”, “daily activities”, and “personal
relationship” in relation to self-perceived AD severity and the EASI. Likewise, the overall
DLQI scores were significantly higher (p < 0.01) in the self-perceived moderate and severe
AD groups than in the mild AD group (Figure 2a). Those with poor and fair self-perceived
overall health rated significantly higher DLQI scores (p < 0.01 and p < 0.05, respectively)
than did those with excellent overall health (Figure 2b). We also observed a significant
increase in the overall DLQI score in the moderate and severe AD groups (p < 0.001 and
p < 0.01, respectively) than in the mild AD group (Figure 2c).
Table 5. Bivariate association between domain-specific, overall DLQI scores and self-perceived AD severity, overall health










Mild 2.90 ± 2.02 1.38 ± 1.62 0.90 ± 1.44 0.81 ± 0.87 0.81 ± 0.92 1.33 ± 1.01 8.14 ± 5.87
Moderate 3.59 ± 1.81 1.63 ± 1.45 0.98 ± 0.96 0.98 ± 0.73 0.94 ± 1.17 1.67 ± 0.86 9.75 ± 4.75
Severe 4.46 ± 1.62 2.37 ± 1.72 1.25 ± 1.51 1.22 ± 0.71 1.41 ± 1.27 1.87 ± 1.00 12.57 ± 4.98
p <0.001 0.006 0.477 0.019 0.013 0.068 <0.001
Overall health rating
Poor 4.41 ± 1.57 2.49 ± 1.46 1.46 ± 1.62 1.00 ± 0.67 1.70 ± 1.41 1.89 ± 0.99 13.14 ± 5.19
Fair 4.40 ± 1.71 2.43 ± 1.88 1.14 ± 1.14 1.03 ± 0.69 1.54 ± 1.19 1.89 ± 0.96 12.69 ± 5.00
Good 3.91 ± 1.83 1.86 ± 1.66 1.08 ± 1.38 1.29 ± 0.86 0.96 ± 1.11 1.60 ± 0.93 10.44 ± 5.16
Excellent 3.07 ± 2.01 1.29 ± 1.54 0.64 ± 1.00 1.19 ± 0.81 0.86 ± 1.09 2.07 ± 1.14 8.93 ± 5.09
p 0.093 0.022 0.199 0.473 0.002 0.113 0.006
EASI a
Mild 2.94 ± 1.73 1.37 ± 1.56 0.79 ± 1.14 0.95 ± 0.77 0.65 ± 0.83 1.44 ± 0.95 7.97 ± 4.53
Moderate 4.65 ± 1.58 2.29 ± 1.65 1.18 ± 1.37 1.13 ± 0.68 1.41 ± 1.27 1.80 ± 0.96 10.87 ± 5.07
Severe 4.50 ± 1.55 2.60 ± 1.64 1.58 ± 1.57 1.30 ± 0.82 1.68 ± 1.34 2.13 ± 0.91 14.09 ± 4.67
p <0.001 <0.001 0.012 0.118 <0.001 0.002 <0.001
Values of domain-specific and overall DLQI expressed as mean ± SD. DLQI: Dermatology Life Quality Index; SD: standard deviation; AD: atopic der-
matitis; EASI: Eczema Area and Severity Index; p-value calculated using the Mann–Whitney U-test or Kruskal–Wallis test; values in bold are significant.
a EASI categorized as: scores <9 (mild), 9–15 (moderate), and >15 (severe).
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3.5. Factors Influencing HRQoL
The models used to estimate the factors influencing domain-specific DLQI are pre-
sented in Table 6. “Leisure”-related QoL was significantly associated with a “family history
of AD” (p < 0.01). Patients with “self-perceived severe AD” were more likely to have
problems with QoL related to “symptoms and feelings” (p < 0.01) and “work and school”
(p < 0.05). However, we found that all the domain-specific DLQI scales (except “work
and school”) were significantly associated with severe EASI scores, indicating that severe
EASI groups are more likely to experience problems with QoL associated with “symptoms
and feelings”, “personal relationships”, and “treatment”. In Table 7, the regression model
revealed that the patients’ HRQoL was considerably influenced by a “family history of
AD” (coefficient = 1.49; 95% CI = 0.02–2.97; p < 0.047). Then again, in “self-reported global
AD severity”, the severe AD group showed a significant association with the overall DLQI
(coefficient = 2.72; 95% CI = 0.38–5.05; p < 0.05), indicating poorer HRQoL than in the
mild AD group. Concurrently, a significant increase in DLQI scores was observed among
patients with moderate and severe EASI scores (coefficient = 1.96, 95% CI = 0.08–3.92,
p < 0.05 and coefficient = 4.35, 95% CI = 1.98–6.72, p < 0.001, respectively) than among those
with mild EASI scores, suggesting a marked impairment in HRQoL with disease severity.
However, no significant association with HRQoL was observed for sociodemographic
parameters and overall health ratings.




































































































DLQI: Dermatology Life Quality Index; Coef B: unstandardized regression coefficient B; CI: confidence interval; ref: used as reference;
NI: not included as not statistically significant at the bivariate level; AD: atopic dermatitis; EASI: Eczema Area and Severity Index;
** p < 0.01; * p < 0.05. a EASI categorized as: scores <9 (mild), 9–15 (moderate), and >15 (severe).
Table 7. Multiple linear regression model for estimating factors influencing the overall DLQI.
Variable
Unstandardized Coefficients 95% Confidence Interval
p
B SE Lower Limit Upper Limit
Marital status
Single ref
Married 1.25 1.07 −0.87 3.38 0.245
Family history of AD No
ref
Yes 1.49 0.74 0.02 2.97 0.047
Self-reported global AD severity
Mild ref
Moderate 1.47 1.28 −1.06 4.01 0.252
Severe 2.72 1.18 0.38 5.05 0.022
Overall health rating
Excellent ref
Good 0.98 1.39 −1.76 3.73 0.481
Fair 1.20 1.59 −1.93 4.35 0.450
Poor 2.02 1.59 −1.12 5.16 0.206
EASI a
Mild ref
Moderate 1.96 0.99 0.08 3.92 0.049
Severe 4.35 1.20 1.98 6.72 <0.001
Constant 4.56 1.79 1.18 7.93 <0.001
DLQI: Dermatology Life Quality Index; ref: used as reference; AD: atopic dermatitis; EASI: Eczema Area and Severity Index; B: unstandardized
regression coefficient B; SE: standard error; values in bold are significant. a EASI categorized as: scores <9 (mild), 9–15 (moderate), and >15 (severe).
4. Discussion
To our knowledge, this is the first study in Bangladesh to assess HRQoL and associated
factors in adults with AD, including a test to investigate the internal consistency reliability
of the DLQI items. Internal consistency reliability measures the homogeneity of multiple
items and is considered a test of the reproducibility of an instrument [16]. For instance,
when a patient’s health status remains stable over time, the results of the instruments
should also remain stable [9]. In our study, we found that the internal consistency reliability
of the DLQI items was good, as judged using Cronbach’s α coefficients and item-total
correlations. These findings are similar to those obtained in the original validation study
and studies using the DLQI in other languages [16,19]. Therefore, we suggest that the
Bangla version of the DLQI may serve as a potential instrument for AD-related health
status measurement in Bangladesh and may contribute to cross-cultural comparison. In
addition, the DLQI offers advantages such as brevity, low burden to participants and data
collectors, and ease of interpretation. Furthermore, the implementation of the DLQI would
help clinicians address specific complications in the patients and categorize which aspects
of the patients’ lives are most severely affected [20].
We observed that poorer HRQoL was associated with the DLQI scores; half of the
participants reported having very large effects on their lives, and these outcomes were
mostly influenced by greater AD severity. Among the participants, the mean DLQI score
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was 11.29, which was relatively higher than that reported in several previous studies
in HICs [21,24–26]. Notably, a cross-sectional population-based study of 602 US adults
reported a mean DLQI score of 4.9 [26]. In contrast, Vakharia et al. found a mean DLQI
score of 10.7 among 265 US adults, while Holm et al. and Sanchez-Perez et al. found mean
DLQI scores of 9.79 and 7.8, respectively, among Danish and Spanish patients [21,24,25].
However, a recent review of 27 studies in Asia found that the DLQI values ranged between
4.8 and 12.0 [27]. Similarly, another review of 32 studies across the US, Europe, and
some Asian countries suggested that the mean DLQI scores varied between 4.9 and 20 [7].
The same review addressed the difficulty in interpreting the overall score because of its
variability across studies and the lack of formal reference values or population normal
scores for formal comparisons. Therefore, more in-depth qualitative research is needed to
confirm these findings.
A substantial number of reports support the role of disease severity as an impor-
tant risk factor for HRQoL impairment in patients with AD [5–8,27]. In our study, we
examined the influence of AD on HRQoL in association with disease severity, measured
using both the clinical objective scoring system EASI and self-rated global AD severity.
Both bivariate and multivariable regression analyses showed that patients with moderate
and severe AD reported worse HRQoL than those with mild AD. This is consistent with
the findings of previous reports that support the hypothesis that HRQoL decreases as
disease severity increases [28,29]. In a systematic review of 15 studies in Asia, 14 studies
showed a significant association between disease severity and HRQoL impairment [27].
In another review, 19 out of 20 studies showed that increased disease severity was signifi-
cantly associated with poorer HRQoL [7]. The effects of AD on impaired HRQoL in our
study seem mostly related to itchiness and embarrassment as these parameters were the
most commonly recorded in the DLQI. Notably, chronic pruritus and eczematous lesions
are the most common symptoms in AD that may affect the patient’s mood and lead to
embarrassment, thereby impacting the patient’s psychological well-being. In contrast,
greater severity was associated with greater impairment in several dimensions of the
DLQI, namely, symptoms and feelings, daily activities, leisure, personal relationships, and
treatment, which is consistent with the findings of previous research [29,30]. Evidence
also suggests that personal relationships were the least affected dimension of HRQoL [7];
however, we found that patients aged between 30 and 50 years experienced more problems
in personal relationships than did those in other age groups. Moreover, we noticed that
having a family history of AD negatively influenced HRQoL, especially leisure-related QoL.
As AD is a restrictive disease that interferes with daily activities, social and interpersonal
relationships would obviously be affected in patients. Furthermore, in LMICs, limited
access to treatment, disease management, lack of formal diagnosis, and low socioeconomic
status, which possibly result in poor follow-up in clinics, may contribute to impaired
HRQoL in patients with AD [11,12,15].
Several studies showed no clear association between the patients’ demographic charac-
teristics and HRQoL impairment [27,31]. Our analysis also did not reveal such an association
between demographic characteristics and HRQoL. However, Holm et al. found more impaired
HRQoL in female patients than in male patients [24]. Therefore, further studies are required
to clarify these relationships. Self-perceived poor overall health was associated with AD in
a study by Silverberg et al. [26]. In our study, the bivariate analysis showed an association
between self-perceived overall health and HRQoL in AD; however, in the regression model
adjusted for potential confounders, this association was diminished. One explanation for this
observation may be that the participants in our study visited a tertiary hospital because of the
main complaint of skin problems. Therefore, disease severity seems to be the main factor that
influences HRQoL in Bangladeshi adult patients with AD.
Several limitations of this study warrant consideration. First, the outcomes of a cross-
sectional study cannot be taken as evidence of causal relationships. Second, the single-institution
study design limits the generalizability of the results. Third, we did not collect information
on the age of AD onset, current treatment therapy, sleep disorders, and HRQoL using generic
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questionnaires. Lastly, we did not include healthy subjects as a control group; therefore, our
observations need further validation. Nevertheless, to our knowledge, this study is the first of
its kind in Bangladesh to document HRQoL among adults with AD. In addition, we used the
objective scoring system EASI to evaluate disease severity. The EASI allows for individual items
to be measured, either separately or in combination, thereby providing a more comprehensive
evaluation and acting as a reference for clinical disease severity in patients. Further research
on a larger patient cohort, including more medical information and utilizing both generic and
dermatology-specific QoL questionnaires, is required to better quantify the effects of AD and
ensure effective treatment.
5. Conclusions
In conclusion, this study demonstrates that Bangladeshi adults with AD experience
substantially poorer HRQoL and that the degree of impairment is markedly influenced by
greater AD severity. Most of the patients experienced the effects of “symptoms and feel-
ings”, “daily activities”, “leisure”, “personal relationships”, and “treatment” on their QoL.
In addition, employing the DLQI instrument seemed beneficial in identifying vulnerable
patients for whom appropriate treatment strategies have to be designed and for whom the
therapeutic response has to be measured. Therefore, we recommend that dermatologists
be aware of the clinical characteristics and negative psychosocial impacts of AD on the
HRQoL of patients with this condition.
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